FGF-21 fusion proteins

Details FGF-21 fusion proteins FGF-21 fusion proteins

2005-05-02

2009-08-18

Allen, Marianne P (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Hormones, e.g., prolactin, thymosin, growth factors, etc.

C530S350000, C530S380000, C530S387100, C435S069700

Reexamination Certificate

active

07576190

ABSTRACT:
The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.

REFERENCES:
patent: 7259248 (2007-08-01), Itoh et al.
patent: 7271149 (2007-09-01), Glaesner et al.
patent: WO 96/04388 (1996-02-01), None
patent: WO 01/18172 (2001-03-01), None
patent: WO 01/36640 (2001-05-01), None
patent: WO 01/72957 (2001-10-01), None
patent: WO 02/46227 (2002-06-01), None
patent: WO 2004/110472 (2004-12-01), None
Angal, S., et al., “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IGG4) Antibody”, Molecular Immunology, Elmsford, NY, US, 30(1):105-108 (1993).
Dikov, M., et al., “A Functional Fibroblast Growth Factor-1 Immunoglobulin Fusion Protein”, Journal of Biological Chemistry, 273(25):15811-15817 (1998).

Affiliated with

Also associated with

Rating

FGF-21 fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FGF-21 fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FGF-21 fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4087348